Association between immune Mediated inflammatory Disease and COVID-19: A Review
Main Article Content
Abstract
COVID-19 outbreak has affected the individuals globally and the individuals with co-morbidities such as diabetes, hypertension, aged individuals with habits such as smoking and Patient with Immune Mediated inflammation (IMI) diseases were considered at the population at higher risk COVID-19 infection and severe progression of the infection. This IMI disease consists of inflammatory bowel disease, connective tissue disease, psoriasis, inflammatory arthritis. Various drug therapies are used for such IMI diseases which include glucocorticoids, cytokine inhibitor, and interlukins which is considered to lower the risk of infection spread. Where as in this review we conclude that the use of glucocorticoids seems to worsen the condition by increase the rate of infection spread and requiring hospitalization, while on other hand the used of cytokine inhibitors and individuals taking methtrexate showed a positive result owing to a good recovers and reduction in the morbidity and mortality
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal is committed to protecting the privacy of authors, reviewers, and readers. The names, email addresses, and other personal information provided to this journal will be used exclusively for the stated purposes of the journal, such as editorial communication and publication processes. This information will not be made available for any other purpose or shared with third parties, except as required by law.